Prognostic factors of dose-response relationship for nodal control in metastatic lymph nodes of cervical cancer patients undergoing definitive radiotherapy with concurrent chemotherapy

Won Hee Lee, Gwi Eon Kim, Yong Bae Kim
Department of Radiation Oncology, Women’s Cancer Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

ABSTRACT

Objective: Regional control is occasionally unsatisfactory in cervical cancer, with the optimal radiation dose for nodal metastases in definitive radiotherapy (RT) with concurrent chemotherapy (CRT) remaining controversial. We investigated dose-response relationship for nodal local control in cervical cancer.

Methods: We identified 115 patients with 417 metastatic nodes who received definitive CRT for cervical cancer with nodal metastases. External beam radiation therapy and brachytherapy plans were summated to determine total dose received by each node. Prognostic factors of nodal control and dose-response relationship were investigated using Cox-regression and restricted cubic spline function.

Results: The 2-year progression-free survival rate was 69.4%. Among 43 patients with failures, 17 patients (37.5%) had regional failure included in first failure sites of which all except one were in-field only regional failures. Total 30 nodes showed recurrence at initial metastatic site after treatment. Neutrophil-to-lymphocyte ratio (NLR) ≥3.1, total radiation dose (minimum dose received by 98% of the target volume in equivalent dose in 2 Gy per fractions), and initial nodal volume ≥5.29 mL were poor prognostic factors (all p<0.050) of nodal local control. Restricted cubic spline functions revealed strongest dose-response relationship in high NLR (NLR ≥3.1) and initial nodal volume ≥5.29 mL subgroup.

Conclusion: Initial nodal volume, radiation dose, and NLR were significant factors of nodal local control in cervical cancer; a stronger dose-response relationship was seen in bulky nodes with high NLR. Clinicians may consider these factors when determining the RT dose and the need for boost to nodal metastases in cervical cancer.

Keywords: Cervical Cancer; Radiotherapy; Brachytherapy; Dose; Lymph Node; Nodal Control
**INTRODUCTION**

The standard treatment for locally advanced cervical cancer is definitive radiotherapy (RT) with concurrent chemotherapy (CRT). In total, 20%–47% of cervical cancer patients are diagnosed with positive metastatic lymph nodes [1,2]. Consensus on radiation dose for cervical tumor and advances in treatment techniques have resulted in outstanding local control rates, but radiation to metastatic lymph nodes lacks consensus concerning the appropriate dose or technique, occasionally resulting in unsatisfactory treatment outcomes [3-7].

The optimal radiation dose for metastatic lymph node in cervical cancer remains not fully understood. Only few studies proposed the minimal dose level for nodes smaller than a specific volume or diameter [8,9]. Other studies have reported the relationship between nodal control and standardized uptake value (SUV) using positron emission tomography (PET) imaging [6,10,11]. Bacorro et al. [12] demonstrated the effect of nodal dose-volume on nodal control probability with greater benefit of additional doses to larger nodes. Meanwhile, no studies have investigated the relationship between neutrophil-to-lymphocyte ratio (NLR) and nodal control. High NLR has been reported as a factor associated with shifting the systemic immune response towards promoting the radioresistance and rapid tumor growth, thus resulting in poor local control and survival outcomes in cervical cancer [13,14]. Nodal control of cervical cancer is likely to be multifactorial, involving all the above factors simultaneously.

In this study, we investigated the dose-response relationship for metastatic lymph nodes in uterine cervical cancer with the prognostic factors of nodal control rate and attempted to propose the optimal dose for a specific metastatic node.

**MATERIALS AND METHODS**

1. **Patient selection**

Patients who received definitive CRT for histologically confirmed cervical cancer between January 2013 and September 2017 at our institution were identified (n=275). Patients without nodal metastases (n=133), who received neoadjuvant chemotherapy before RT (n=12), patients without their first follow-up visit after treatment (n=7), and those who did not finish the planned treatment (n=8) were excluded. Finally, 115 patients with 417 nodal metastases were included. The need for informed consent was waived due to the study’s retrospective nature. The Institutional Review Board of Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea approved this study (approval number: 4-2020-1005).

2. **Pre-treatment evaluation and treatment protocols**

All patients diagnosed with cervical cancer underwent abdomino-pelvic magnetic resonance imaging (MRI), and PET-computed tomography (CT), with baseline studies consisting of pelvic...
examination, chest X-ray, intravenous pyelogram, cystography, sigmoidoscopy, and blood test for staging. The NLR was calculated based on complete blood cell counts performed at baseline study. The 2009 International Federation of Gynecology and Obstetrics (FIGO) staging system was used. Metastatic nodes were defined by radiologists based on significant PET uptake, short-axis diameter of ≥10 mm, round shape, and/or heterogeneous enhancement.

Patients diagnosed with FIGO stage bulky IB, or FIGO stage IIB or higher received definitive CRT. A flowchart of the treatment for locally advanced cervical cancer in patients receiving definitive CRT in our institution is shown in Fig. 1. Detailed indications and treatment schemes for external beam radiation therapy (EBRT) and high-dose rate (HDR)-intracavitary brachytherapy (ICBT) are described elsewhere [15,16]. EBRT was performed using Elekta Infinity linear accelerator and Versa HD (Elekta AB, Stockholm, Sweden) for 3-dimensional conformal radiation therapy (3D-CRT) while TomoTherapy (Accuray Inc., Madison, WI, USA) was used for intensity-modulated radiation therapy (IMRT). For EBRT planning, Pinnacle (version 9.10; Philips Radiation Oncology Systems, Milpitas, CA, USA) and TomoHD radiation treatment planning system (version 5.1.6.1; Accuray Inc.) was used for 3D-CRT and TomoTherapy, respectively. For the treatment planning of HDR-ICBT, a CT-based treatment plan was used. HDR-ICBT was performed using Afterloading MultiSource (version 4.15.1; Eckert & Ziegler BEBIG, Berlin, Germany) with HDR plus (version 3.0; Eckert & Ziegler BEBIG) for treatment planning. On nearing the completion of HDR-ICBT and initial EBRT, CT-simulation was performed to consider boosts to metastatic nodes. Sequential boost (SEB) to the gross metastatic nodes was administered to patients receiving 1.8–2.2 Gy per fraction, followed by another CT-simulation. Based on the physician’s discretion, additional boost was administered if necessary. After the introduction of IMRT, simultaneous-integrated boost was given followed by SEB when nodal response was insufficient after initial EBRT. Planning target volume or nodal boost was defined as the nodal gross tumor volume with a 3–5-mm margin. The boost volume was reduced according to the latest CT-simulation whenever nodal boost was performed.
3. Follow-up after treatment

One month after the initial treatment, cervical cancer patients underwent follow-up examinations every 3 months for the first 2 years and once per year thereafter. Patients underwent pelvic examination, tumor marker evaluation, and imaging by CT and/or MRI. PET-CT was performed when findings suggestive of recurrence were noted on CT and/or MRI or tumor marker elevation occurred without evidence of recurrence on CT and/or MRI. Toxicity was evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Late toxicities were defined as those occurring 3 months post-treatment.

4. Assessment of nodal characteristics

All CT and PET-CT data of each patient were imported into MIM software (MIM Software Inc., Cleveland, OH, USA). All metastatic nodes were separately contoured on MIM software. The volume (in mL) of each node was assessed using both initial CT-simulation and first boost CT-simulation. The ratio of the nodal volume at initial CT-simulation to that at first boost CT-simulation was calculated. The maximum and mean PET SUV values of each node were measured by fusing PET-CT and CT-simulation. The mean dose and the minimum dose received by 98% of the target volume (D$_{98\%}$) to each nodal planning target volume was measured in biologically equivalent dose in 2 Gy per fractions (EQD2) with an α/β value of 10 Gy. The summation of radiation dose was performed using MIM software after importing and summing all EBRT and HDR-ICBT plans for each patient, as both treatment plans were based on CT.

5. Statistical analysis

The Kaplan-Meier method and log-rank test were used to estimate and compare ever-nodal recurrence-free rates, progression-free survival (PFS) and overall survival (OS). Ever-nodal recurrence-free interval was measured from the diagnosis date to the date of ever-recurrence in the identical node, considering each node as an independent entity. In case of patient death or salvage surgery, the node was censored. If a viable tumor was found after salvage surgery, then the node was considered to recur at the time of surgery. The Cox-regression model was used to identify factors associated with ever-recurrence in a single node. Regarding the patterns of first failures, regional failure was defined as recurrence in regional lymph node nodes including parametrial, obturator, internal and external iliac, sacral, presacral, common iliac and para-aortic lymph node. Distant failure was defined as any recurrence except local and regional failure. For evaluating NLR and initial nodal volume, the optimal cutoff points for time to ever-nodal recurrence were calculated according to the Contal and O’Quigely’s method. Significant factors (p<0.050) in univariate analysis with Cox-regression were entered into the multivariate analysis. For dose-response analysis, patients were grouped into NLR-low and NLR-high groups. Restricted cubic spline function was implemented to examine the non-linear relationship of the ever-nodal recurrence hazard ratio (HR) against nodal PTV D$_{98\%}$ in EQD2 which remained significant after multivariate Cox-regression analysis. Restricted cubic spline function, a form of regression analysis, was used because not only it can decipher a non-linear relationship between associated factors, but also can take time factor into account which allows to reveal the relationship between HR and a certain clinical factor. Statistical analyses were performed using SPSS software (version 25.0; IBM Inc., Armonk, NY, USA) and R version 4.0.2 (R Foundation, Vienna, Austria; https://www.R-project.org/). The Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines were followed in the analysis for this study [17].
RESULTS

Patient and treatment characteristics of the 115 patients are listed in Table 1. Most patients were squamous cell carcinoma (97 patients, 84.3%). HDR-ICBT was performed in all patients except 3 patients whose tumor response was poor after EBRT. The nodal and treatment characteristics of all 417 individual nodes are listed in Table 2, where 411 nodes (98.6%) received any form of boost, and 98 nodes (23.5%) were classified as para-aortic nodes.

The median follow-up duration for all patients was 44.5 months (range, 8.6–97.6). The 2-year and 5-year OS rates were 95.4% and 85.8%, respectively. The 2-year and 5-year PFS rates were 69.4% and 62.1%, respectively. Forty-three patients (37.4%) experienced any form of failure. The most common form of first failure was distant only failure (20 patients, 46.5%), followed by regional and distant failure (9 patients, 20.0%), and regional only failure (5 patients, 11.6%) (Table S1). Among patients who had regional failure included in first failure site (17 patients, 39.5%), recurred regional nodes were in-field only regional failures in 16 patients, and 1 patient had both in-field and out-field regional failures. Patients who had regional failure included in first failure site showed 5-year OS rate of 37.2% (vs. 91.8% in all)

### Table 1. Patient and treatment characteristics

| Characteristic                  | Value     |
|--------------------------------|-----------|
| Age (yr)                        | 51 (28–79) |
| Pathology                       |           |
| Squamous cell carcinoma         | 97 (84.3) |
| Adenocarcinoma                  | 13 (11.3) |
| Others                          | 5 (4.3)   |
| FIGO stage                      |           |
| IA                              | 3 (2.6)   |
| IB                              | 19 (16.5) |
| IIA                             | 4 (3.5)   |
| IIB                             | 66 (57.4) |
| IIIA                            | 2 (1.7)   |
| IIIB                            | 15 (13.0) |
| IVA                             | 6 (5.2)   |
| No. of positive nodes           | 2 (1–15)  |
| RT technique                    |           |
| 3D-CRT                          | 76 (66.1) |
| IMRT                            | 31 (27.0) |
| Combined                        | 8 (7.0)   |
| RT field                        |           |
| Whole pelvis                    | 21 (18.3) |
| Semi-extended field             | 45 (39.1) |
| Extended field                  | 49 (42.6) |
| Whole-pelvis dose               |           |
| 45 Gy/25 fractions              | 102 (88.7) |
| 41.4 Gy/23 fractions            | 3 (2.6)   |
| 50.4 Gy/28 fractions            | 10 (8.7)  |
| HDR-ICBT dose per fraction (Gy) | 5.0 (2.0–6.0) |
| HDR-ICBT fractions              | 6 (5–10)  |
| Chemotherapy regimen            |           |
| Cisplatin                       | 82 (71.3) |
| 5-Fluorouracil/cisplatin        | 28 (24.3) |
| Others                          | 5 (4.4)   |
| NLR                             | 2.7 (0.9–9.7) |

Values are presented as number (%) or median (range).

FIGO, International Federation of Gynecology and Obstetrics; HDR, high-dose rate; ICBT, intracavitary brachytherapy; IMRT, intensity-modulated radiation therapy; NLR, neutrophil-to-lymphocyte ratio; RT, radiotherapy; 3D-CRT, 3-dimensional conformal radiation therapy.
other patients, \( p < 0.001, \text{Fig. S1} \). In multivariate analysis of OS, pathology of adenocarcinoma (vs. squamous cell carcinoma), higher FIGO stage, and primary mass size were significant factors (Table S2) whereas pathology of adenocarcinoma (vs. squamous cell carcinoma), higher FIGO stage, and NLR \( \geq 3.1 \) (vs. <3.1) were significant factors regarding PFS (Table S3). The 1-year and 2-year PFS rates for NLR \( \geq 3.1 \) (vs. <3.1) patients were 53.8% (vs. 90.8%) and 48.5% (vs. 80.2%), respectively (\( p = 0.002, \text{Fig. S2} \)). Among all patients, 14 experienced grade \( \geq 3 \) treatment-related toxicities (Table S4). For all patients with grade 3 or higher toxicities, RT plans were reviewed in search for those related to lymph node boosts. Plan reviews revealed one patient with grade 4 duodenum ulcer perforation that occurred 4 months after definitive CRT with boost to metastatic para-aortic node to 57.25 Gy\( _{\text{EQD2}} \).

The median follow-up duration for total nodes was 34.7 months (range, 5.6–95.2). In total, 30 nodes showed recurrence at the initial site. The 1-year and 2-year ever-nodal recurrence-free rates were 95.4% and 93.7%, respectively (Fig. 2A). Table 3 shows the results of Cox-regression analysis for ever-nodal recurrence of each node. An NLR of 3.1 and an initial nodal volume of 5.29 mL were found to be the optimal cutoff values. In multivariate analysis, NLR \( \geq 3.1 \) (vs. <3.1), initial nodal volume \( \geq 5.29 \text{mL} \) (<5.29 mL), and total (EBRT+HDR-ICBT) \( D_{98\%} \) of nodal PTV in EQD2 (all \( p < 0.050 \)) were significant prognostic factors for ever-nodal recurrence. In the NLR-low (NLR <3.1) and NLR-high (NLR \( \geq 3.1 \)) groups, the 2-year ever-

### Table 2. Nodal characteristics

| Characteristic                        | Value          |
|---------------------------------------|----------------|
| **Pathology**                         |                |
| Squamous cell carcinoma               | 344 (82.5)     |
| Adenocarcinoma                        | 64 (15.3)      |
| Others                                | 9 (2.2)        |
| **Location**                          |                |
| Parametrial                           | 6 (1.4)        |
| Obturator                             | 114 (27.3)     |
| Internal iliac                        | 22 (5.3)       |
| External iliac                        | 94 (22.5)      |
| Common iliac                          | 82 (19.7)      |
| Presacral                             | 1 (0.2)        |
| Para-aortic                           | 98 (23.5)      |
| **Initial nodal volume (mL)**         | 2.24 (0.22–112.06) |
| **Nodal volume before boost (mL)**    | 0.95 (0.00–39.02)   |
| **Ratio of initial nodal volume to nodal volume before boost** | 0.57 (0.01–3.98) |
| **Nodal max SUV**                     | 4.20 (0.20–20.70)   |
| **Nodal mean SUV**                    | 2.20 (0.10–11.10)   |
| **Type of nodal boost**               |                |
| SEB                                   | 286 (68.6)     |
| SIB only                              | 16 (3.8)       |
| SIB followed by SEB                   | 109 (26.1)     |
| No boost                              | 6 (1.4)        |
| **Prescribed radiation dose, Gy\(_{\text{EQD2}}\)** | 53.10 (40.71–71.92) |
| **EBRT \( D_{\text{max}} \) of nodal PTV, Gy\(_{\text{EQD2}}\)** | 53.44 (31.13–70.75) |
| **EBRT \( D_{\text{mean}} \) of nodal PTV, Gy\(_{\text{EQD2}}\)** | 54.40 (35.28–73.70) |
| **HDR-ICBT \( D_{\text{max}} \) of nodal PTV, Gy\(_{\text{EQD2}}\)** | 2.43 (0.00–17.74) |
| **HDR-ICBT \( D_{\text{mean}} \) of nodal PTV, Gy\(_{\text{EQD2}}\)** | 2.95 (0.00–25.21) |
| **Total (EBRT+HDR-ICBT) \( D_{\text{max}} \) of nodal PTV, Gy\(_{\text{EQD2}}\)** | 56.87 (31.13–79.22) |
| **Total (EBRT+HDR-ICBT) \( D_{\text{mean}} \) of nodal PTV, Gy\(_{\text{EQD2}}\)** | 58.36 (35.28–85.08) |

Values are presented as number (%) or median (range). \( D_{\text{max}} \), mean dose; \( D_{\text{mean}} \), minimum dose received by 98% of the target volume; EBRT, external beam radiation therapy; EQD2, equivalent dose in 2 Gy per fractions; HDR, high-dose rate; ICBT, intracavitary brachytherapy; SIB, simultaneous integrated boost; SEB, sequential boost; SUV, standardized uptake value; PTV, planning target volume.

\( ^* \)Equivalent dose at fractionation of 2 Gy (\( \alpha/\beta=10 \text{Gy} \)).
nodal recurrence rates were 97.5% and 88.4%, respectively (p=0.002) (Fig. 2B). In nodes with initial volume <5.29 mL and ≥5.29 mL, the 2-year ever-nodal recurrence-free rates were 96.5% and 83.0%, respectively (p<0.001) (Fig. 2C).

For further analysis of dose-response relationship depending on risk factors, total nodes were stratified into NLR-high and NLR-low groups. Fig. 3 shows a relationship between radiation dose and relative HR of ever-nodal recurrence using restricted cubic spline function for the NLR-low and NLR-high groups, respectively. In the NLR-low group, the relative HR of ever-nodal recurrence showed much weaker relationship with the radiation dose in any dose range than that in the NLR-high group regardless of nodal volume. For 50 GyEQD2 and 60 GyEQD2, the respective relative HRs in NLR-low group were approximately 2.68 (95% confidence interval [CI]=1.21–5.93) and 0.30 (95% CI=0.17–0.52) for an initial nodal volume of <5.29 mL and 9.25 (95% CI=1.98–43.24) and 0.99 (95% CI=0.31–3.13) for an initial nodal volume of ≥5.29 mL.
The initial nodal volume did not significantly affect the dose-response relationship in the NLR-low group (p=0.094). For 50 Gy\textsubscript{EQD2} and 60 Gy\textsubscript{EQD2} in NLR-high group, the relative HRs were 1.25 (95% CI=0.73–2.14) and 0.39 (95% CI=0.27–0.57) for an initial nodal volume of <5.29 mL and 10.20 (95% CI=3.97–26.17) and 3.21 (95% CI=1.57–6.56) for an initial volume of ≥5.29 mL. In the NLR-high group, nodes with an initial nodal volume of ≥5.29 mL showed a significantly higher relative HR than nodes with an initial volume of <5.29 mL (p<0.001), showing the most vivid relationship between relative HR of ever-nodal recurrence and radiation dose.

### Table 3. Cox regression model for ever-nodal recurrence

| Variable                                      | Univariate analysis | Multivariate analysis |
|-----------------------------------------------|---------------------|-----------------------|
| Pathology                                     | HR (95% CI)         | p-value               |
| Squamous cell carcinoma                       | Reference value     | 0.863                 |
| Adenocarcinoma                                | 1.31 (0.50–3.43)    | 0.588                 |
| Others                                        | NA                  | 0.980                 |
| NLR (≥3.1 vs. <3.1)                           | 3.10 (1.43–6.72)    | 0.004                 |
| RT modality (IMRT vs. 3D-CRT)                 | 0.35 (0.12–1.02)    | 0.156                 |
| RT field                                      | Reference value     | 0.273                 |
| Whole pelvis                                  | 0.75 (0.14–4.09)    | 0.739                 |
| Semi-extended field                           | 1.70 (0.40–7.22)    | 0.472                 |
| Extended field                                |                     |                       |
| No. of positive nodes                         | 1.04 (0.95–1.14)    | 0.353                 |
| Location (para-aortic or common iliac vs. pelvic) | 2.82 (1.28–6.20)    | 0.010                 |
| Total (EBRT+HDR-ICBT) \(D_{\text{mean}}\) of nodal PTV (per 1 Gy\textsubscript{EQD2}\(^*\)) | 0.87 (0.83–0.92)    | <0.001                |
| Total (EBRT+HDR-ICBT) \(D_{\text{mean}}\) of nodal PTV (per 1 Gy\textsubscript{EQD2}\(^*\)) | 0.89 (0.84–0.94)    | <0.001                |
| Initial nodal volume (≥5.29 mL vs. <5.29 mL)  | 3.99 (1.95–8.18)    | <0.001                |
| Ratio of nodal volume before EBRT to that after EBRT (per 1) | 1.52 (0.69–3.37)    | 0.298                 |
| Nodal max SUV                                 | 1.06 (0.98–1.15)    | 0.118                 |
| Nodal mean SUV                                | 1.13 (0.92–1.39)    | 0.263                 |

**Notes:** CI, confidence interval; NA, not applicable; \(D_{\text{mean}}\), mean dose received by target volume; \(D_{\text{mean}}\), minimum dose received by 98% of the target volume; EBRT, external beam radiation therapy; HDR, high-dose rate; HR, hazard ratio; ICBT, intracavitary brachytherapy; IMRT, intensity-modulated radiation therapy; NLR, neutrophil-to-lymphocyte ratio; PTV, planning target volume; RT, radiotherapy; SUV, standardized uptake value; 3D-CRT, 3-dimensional conformal radiation therapy.

\(*\) Equivalent dose at fractionation of 2 Gy (\(\alpha/\beta=10\) Gy).

**Fig. 3.** Restricted cubic spline functions for radiation equivalent dose in a fraction of 2 Gy according to initial nodal volume in NLR-low (≤3.1) (A) and NLR-high (≥3.1) (B) groups.

NLR, neutrophil-to-lymphocyte ratio.
DISCUSSION

To the best of our knowledge, this is the first study to demonstrate the dose-response relationship combining the above factors to suggest nodal subgroups for boost and target doses for a specific metastatic lymph node in cervical cancer. Our study demonstrated the radiation dose-response relationship in metastatic lymph nodes in cervical cancer and prognostic factors of nodal control rate. NLR, a recently known key prognostic factor in cervical cancer was revealed as a novel nodal response prognostic factor. A stronger dose-response relationship was noted in the NLR-high group compared to that in the NLR-low group, especially in bulky nodes.

With the image-guided brachytherapy, local control rate in cervical cancer has significantly improved, but this has not been the case for regional control [3-5]. The recently revised 2018 FIGO staging system for cervical cancer now directly stages any cervical tumor with nodal metastases to FIGO stage IIIC, as they have poorer survival compared to those without nodal metastases [18]. Recently published EMBRACE-I study also underlines the significance of nodal control, as para-aortic nodal failures occur frequently along with total nodal failure rate of 16% in node-positive patients [19,20]. Our study showed that 17 (14.8%) of the 115 cervical cancer patients had any form of regional failure as first failure (Table S1). More importantly, these patients had remarkably poor survival outcomes compared to other patients. Notably, all these patients had in-field regional failures, suggesting the importance of specifying the high-risk metastatic nodes and giving sufficient radiation dose to improve survival outcomes in these patients. To improve nodal control, some studies have proposed threshold doses for metastatic nodes with certain sizes [9,21,22], while others suggested nodal SUV as a prognostic factor for nodal control as well [11,23]. Nevertheless, these studies lacked comprehension of the multifactorial process of nodal control. Here, not only radiation dose and volume but also nodal SUV, hematologic factors, and interim volume response were all combined to identify the most significant prognostic factors of nodal control.

Recent study demonstrated a continuous dose-volume relationship, without taking time factor into account [12]. Moving further, our study is the first to report the dose-response relationship with taking time factor into account. To accurately determine the radiation dose-response relationship, we incorporated all EBRT and HDR-ICBT plans to precisely measure the affected dose in each node. As a result, location of nodes which was significant factor in univariate Cox-regression for ever-nodal recurrence, were not significant after multivariate analysis. Brachytherapy is known to affect pelvic cavity nodes at the dose of 2–4 GyEQD2, in accordance with our results [24-26]. It is reasonable to understand that the lower nodal recurrence rate of pelvic nodes compared to para-aortic nodes is partly due to the additional scattered dose from HDR-ICBT.

Pre-existing high NLR and tumor-related leukocytosis are significantly related to poor tumor response, decreased OS and PFS in cervical cancer although the exact mechanism remains unknown [13,27,28]. Studies have found that pre-existing high NLR and tumor-related leukocytosis are consequence of systemic inflammatory response related to carcinogenesis and tumor progression [29]. Moreover, granulocyte colony-stimulating factor released by the tumor could increase neutrophil counts along with myeloid-derived suppressor cells, which cause rapid progression and radioresistance [14]. Therefore, we believed NLR, a factor that reflects the systemic inflammatory response and tumor microenvironment, could be used to predict nodal response as well. In this study, NLR was significantly associated with poor nodal control as well as decreased PFS. This study is the first to identify NLR as
an independent factor affecting nodal control, emphasizing that radiation dose should be individualized according to the patient’s immuno-oncologic characteristics.

Here, PET SUV did not appear to be a significant factor of nodal recurrence, in contrast to previous studies [10,11]. Limited analysis upon interim metabolic response because of the lack of interim PET in our patients might have caused this discrepancy, as some studies suggested that metabolic response is related to survival outcomes and nodal control [6,10]. It is well-known that metastatic nodes undergo substantial volume change during RT [30]. However, interim volume response was not significant factor of nodal recurrence, contrary to the finding of a previous study [31]. However, Bacorro et al. [12] suggested that interim radiologic response might not be a reliable indicator of nodal control, in line with our results. Incorporating other significant factors such as NLR might have also contributed to the dilution of the significance of nodal SUV or interim volume response.

Restricted cubic spline functions demonstrated the strongest dose-response relationship in the NLR-high and initial nodal volume ≥5.29 mL subgroup. This provides valuable information as it could suggest the nodal subgroup where boost should be considered along with possible target doses. The positive dose-response relationship in high NLR, initial nodal volume ≥5.29 mL subgroup stretched beyond 60 GyEQD. In this group, nodal boost beyond 60 GyEQD seems a considerable option to achieve maximal nodal control. Yet, the risk-benefit of nodal boost should be carefully weighted, although only one ≥G3 toxicity related to nodal boost was noted. It is uncertain whether the benefit of nodal control outweighs the risk of boost even in these nodes. Considering the excellent absolute control rate in nodes with low NLR and initial nodal volume of <5.29 mL, 50–55 Gy using simultaneous integrated boost without additional SEB seems to be a reasonable option. By omitting unnecessary boost, the risk of radiation-related toxicity can be reduced along with overall treatment time, a well-known factor related to treatment outcomes in cervical cancer [32-34].

There are several limitations in this study. The metastatic nodes were not pathologically confirmed, but clinically diagnosed based on suspicious findings from imaging studies. This was a retrospective study performed at a single institution with a limited number of patients. The value of risk groups based on NLR should also be interpreted carefully, because validation using an independent dataset is necessary to solidify the results from this study. Dose-response relationship regarding nodal subgroups warrant caution also. Number of nodes per subgroups are limited, resulting in some widely varying CIs. Nonetheless, there are some apparent strengths of our study. For the first time, it investigated the multifactorial process in nodal response and identified NLR as a novel factor affecting nodal control. We demonstrated the dose-response relationship as a continuous function of radiation dose incorporating both EBRT and HDR-ICBT dose in different clinical risk groups, suggesting optimal subgroup where nodal boost would most likely come with the largest clinical benefit.

In conclusion, we identified initial nodal volume, radiation dose, and NLR as significant nodal control factors. A strong dose-response relationship was noted in the NLR-high and initial nodal volume ≥5.29 mL subgroup beyond 60 GyEQD. Clinicians may consider these prognostic factors and give boosts to bulky nodes in high NLR patients wherein the dose-response benefit is greatest, while carefully weighing the risk-benefit ratio. Further validation is necessary to clarify the oncologic outcomes of individualized nodal boosts in cervical cancer patients receiving definitive CRT.
SUPPLEMENTARY MATERIALS

**Table S1**
Pattern of first failures
Click here to view

**Table S2**
Cox regression model for overall survival
Click here to view

**Table S3**
Cox regression model for progression-free survival
Click here to view

**Table S4**
Grade ≥3 treatment-related toxicities
Click here to view

**Fig. S1**
Kaplan-Meier curves of overall survival in total patients according to regional nodal failure as first failure.
Click here to view

**Fig. S2**
Kaplan-Meier curves of progression-free survival in total patients according to NLR.
Click here to view

REFERENCES

1. Benedetti-Panici P, Maneschi F, Scambia G, Greggi S, Cutillo G, D’Andrea G, et al. Lymphatic spread of cervical cancer: an anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy. Gynecol Oncol 1996;62:19-24.
   [PUBMED] [CROSSREF]

2. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 2010;28:2108-13.
   [PUBMED] [CROSSREF]

3. Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, et al. Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 2016;120:428-33.
   [PUBMED] [CROSSREF]

4. Nomden CN, de Leeuw AA, Roesink JM, Tersteeg RJ, Moerland MA, Witteveen PO, et al. Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience. Radiother Oncol 2013;107:69-74.
   [PUBMED] [CROSSREF]
5. Castelnau-Marchand P, Chargari C, Maroun P, Dumas I, Del Campo ER, Cao K, et al. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer. Gynecol Oncol 2015;139:288-94.

6. Yoon MS, Ahn SJ, Nah RS, Chung WK, Song HC, Yoo SW, et al. Metabolic response of lymph nodes immediately after RT is related with survival outcome of patients with pelvic node-positive cervical cancer using consecutive [18F]fluorodeoxyglucose-positron emission tomography/computed tomography. Int J Radiat Oncol Biol Phys 2012;84:e491-7.

7. Small W Jr, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys 2007;68:1081-7.

8. Ariga T, Toita T, Kasuya G, Nagai Y, Inamine M, Kudaka W, et al. External beam boost irradiation for clinically positive pelvic nodes in patients with uterine cervical cancer. J Radiat Res 2013;54:690-6.

9. Hata M, Koike I, Numazaki R, Asai-Sato M, Kasuya T, et al. Radiation therapy for pelvic lymph node metastasis from uterine cervical cancer. Gynecol Oncol 2013;131:99-102.

10. Rash DL, Lee YC, Kashefi A, Durbin-Johnson B, Mathai M, Valicenti R, et al. Clinical response of pelvic and para-aortic lymphadenopathy to a radiation boost in the definitive management of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2013;87:317-22.

11. Ramlov A, Kroon PS, Jürgenliemk-Schulz IM, De Leeuw AA, Gormsen LC, Fokdal LU, et al. Impact of radiation dose and standardized uptake value of (18)FDG PET on nodal control in locally advanced cervical cancer. Acta Oncol 2015;54:1567-73.

12. Bacorro W, Dumas I, Escande A, Gouy S, Bentivegna E, Morice P, et al. Dose-volume effects in pathologic lymph nodes in locally advanced cervical cancer. Gynecol Oncol 2018;168:461-7.

13. Cho Y, Kim KH, Yoon HI, Kim GE, Kim YB. Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients. Ann Oncol 2016;27:2067-74.

14. Mabuchi S, Matsumoto Y, Kawano M, Minami K, Seo Y, Sasano T, et al. Uterine cervical cancer displaying tumor-related leukocytosis: a distinct clinical entity with radioresistant feature. J Natl Cancer Inst 2014;106:1417.

15. Choi J, Yoon HI, Lee J, Keum KC, Kim GE, Kim YB. Optimal extent of prophylactic irradiation of paraaortic lymph nodes in patients with uterine cervical cancer. PLoS One 2015;10:e0145158.

16. Kim KH, Kim S, Kim GE, Koom WS, Kim SW, Nam EJ, et al. De-escalation of the cumulative central radiation dose according to the tumor response can reduce rectal toxicity without compromising the treatment outcome in patients with uterine cervical cancer. Gynecol Oncol 2015;139:439-46.

17. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 2015;162:55-63.

18. Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grennan S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 2019;145:129-35.

19. Pötter R, Tanderup K, Schmid MP, Jürgenliemk-Schulz I, Haie-Meder C, Fokdal LU, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-1): a multicentre prospective cohort study. Lancet Oncol 2021;22:538-47.

20. Nomden CN, Pötter R, de Leeuw AA, Tanderup K, Lindegaard JC, Schmid MP, et al. Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: patterns of failure in the EMBRACE study cohort. Radiother Oncol 2019;134:185-90.
21. Gogineni E, Bloom B, Diaz Molina F, Villella J, Goenka A. Radiotherapy dose escalation on pelvic lymph node control in patients with cervical cancer. Int J Gynecol Cancer 2021;31:524-9.

22. Vargo JA, Kim H, Choi S, Sukumvanich P, Olawaiye AB, Kelley JL, et al. Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era. Int J Radiat Oncol Biol Phys 2014;90:1091-8.

23. Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I. Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys 2004;59:706-12.

24. Bacorro W, Dumas I, Levy A, Rívin Del Campo E, Canova CH, Felefy T, et al. Contribution of image-guided adaptive brachytherapy to pelvic nodes treatment in locally advanced cervical cancer. Brachytherapy 2017;16:366-72.

25. Lee YC, Rash DL, Stern RL, Mayadev JS. The equivalent dose contribution from high-dose-rate brachytherapy to positive pelvic lymph nodes in locally advanced cervical cancer. Brachytherapy 2013;12:555-9.

26. van den Bos W, Beriwal S, Velema L, de Leeuw AA, Nomden CN, Jürgenliemk-Schulz IM. Image guided adaptive brachytherapy for cervical cancer: dose contribution to involved pelvic nodes in two cancer centers. J Contemp Brachytherapy 2014;6:21-7.

27. Lee YY, Choi CH, Kim HJ, Kim TJ, Lee JW, Lee JH, et al. Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res 2012;32:1555-61.

28. Mizunuma M, Yokoyama Y, Futagami M, Aoki M, Takai Y, Mizunuma H. The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer. Int J Clin Oncol 2015;20:989-96.

29. Mabuchi S, Matsumoto Y, Isohashi F, Yoshioka Y, Ohashi H, Morii E, et al. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. Gynecol Oncol 2011;122:25-32.

30. Schippers MG, Bol GH, de Leeuw AA, van der Heide UA, Raaymakers BW, Verkooijen HM, et al. Position shifts and volume changes of pelvic and para-aortic nodes during IMRT for patients with cervical cancer. Radiother Oncol 2014;111:442-5.

31. Wakatsuki M, Ohno T, Kato S, Ando K, Noda SE, Kiyohara H, et al. Impact of boost irradiation on pelvic lymph node control in patients with cervical cancer. J Radiat Res 2014;55:139-45.

32. Lanciano RM, Pazak TF, Martz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys 1993;25:397-41.

33. Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. 1. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:1275-88.

34. Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann TJ, Kinsella TJ, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995;32:1301-7.